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Abstract
The envelope glycoprotein of HIV-2 ROD10 has the intriguing ability to enhance the rate of viral particle release from infected cells.
However, not all HIV-2 envelope glycoproteins are active in this regard. Indeed, we have previously noted that, despite a high degree of
identity with that of ROD10, the envelope protein of the ROD14 isolate was unable to enhance virus production. In this study, site-directed
mutagenesis was employed to reveal that a single naturally occurring alanine-to-threonine substitution at position 598, located in the
extracellular part of the TM subunit, fully accounted for the lack of activity of the ROD14 Env in HeLa and 12D7 cells. A second mutation
at position 422, substituting a lysine residue in ROD10 for an arginine in ROD14, was additionally required for efficient virus release from
infected H9 cells, suggesting cell-type-specific requirements for this activity. Interestingly, the ROD14 Env protein exhibited a trans-
dominant negative effect on particle release by ROD10 Env, suggesting that the viral release activity of the HIV-2 ROD envelope protein
may be regulated by its ability to assemble into functional oligomeric structures.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Vpu is a human immunodeficiency virus type 1 (HIV-
1)-specific protein that enhances the release of viral parti-
cles from infected cells (Strebel et al., 1989; Terwilliger et
al., 1989). Despite the absence of a genuine vpu gene, some
isolates of HIV-2, such as ROD10 and ST, express a func-
tional homologue to Vpu. Indeed, the envelope glycoprotein
of these viruses was shown to enhance the rate of viral
particle production in a manner indistinguishable from that
of genuine Vpu (Bour et al., 1996; Ritter et al., 1996). Both
Vpu and the ROD10 Env augment the release of chimeric
viruses bearing the gag-pol regions of heterologous retro-
viruses, including HIV-1, HIV-2, and simian immunodefi-
ciency virus (SIV) (Bour and Strebel, 1996; Go¨ttlinger et
al., 1993), suggesting a common mechanism of action be-
tween these two proteins in enhancing particle release.
However, the precise mechanism by which Vpu enhances
virus release has not been fully uncovered despite recent
data suggesting that it may involve the formation of an ion
channel by oligomeric Vpu (Ewart et al., 1996; Grice et al.,
1997; Schubert et al., 1996b). One intriguing possibility is
that the HIV-2 Env could similarly mediate the release of
viral particles through the formation of a membrane pore.
This is supported by the fact that Vpu and the HIV-2 Env
both require the presence of a functional trans-membrane
domain for their activity (Bour et al., 1996; Schubert et al.,
1996a) and adopt an oligomeric structure favorable to the
formation of a membrane pore (Maldarelli et al., 1993; Rey
et al., 1990).
Expression of the vpu gene is regulated at the transla-
tional level. Indeed, a number of HIV-1 isolates that harbor
a functional vpu coding sequence do not encode the Vpu
protein due to the absence of a functional initiation codon
(Korber et al., 1997). Although the nature of the selection
pressure driving the elimination of Vpu is presently not
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clear, the resulting decrease in viral particle production
could contribute to the establishment of long-lasting latent
infections. Previous studies have suggested that HIV-2 also
has the ability to regulate the particle release activity of its
envelope protein by modifying the length of the transmem-
brane (TM) subunit cytoplasmic tail (Ritter et al., 1996).
However, such putative correlation between the length of
the cytoplasmic tail and the presence of particle release-
promoting activity could not be confirmed in the case of the
ROD10 isolate (Bour et al., 1999b). The present work aims
at resolving this apparent contradiction by defining the de-
terminants in the ROD10 envelope protein that regulate its
particle release activity. To this end, we examined the par-
ticle release activity of ROD14, a molecular clone of HIV-2
closely related to ROD10 that originated from the same
patient (Clavel et al., 1986; Naidu et al., 1988; Ryan-Gra-
ham and Peden, 1995). We demonstrate that despite its high
level of homology with the active ROD10 envelope, the
ROD14 envelope does not support viral particle release.
Site-directed mutagenesis performed on the ROD14 as
well as the ROD10 envelope shows that the ability of
HIV-2 ROD to enhance viral particle release is not
regulated by the length of the cytoplasmic tail but by two
amino acid substitutions in the ectodomain of the envelope
glycoprotein.
Results
Delineation of a functional region for particle release
activity within the extracellular domain of Env
We have previously reported that the envelope protein of
ROD14, an HIV-2 molecular clone closely related to
ROD10, was unable to enhance viral particle release (Bour
et al., 1999b). We have also shown that this activity is not
regulated by the length of the Env protein cytoplasmic tail
(Bour et al., 1999b). To define the regions in HIV-2 Env
important for viral particle release, chimeras were con-
structed between the ROD10 and ROD14 envelope genes
and cloned under the transcriptional control of the CMV
promoter (pCM10 and pCM14, respectively; Fig. 1A). The
pCM14.Pst10 chimera contains the PstI fragment from the
ROD10 Env and introduces amino acid changes 422RK and
598TA as well as a premature stop codon that truncates the
cytoplasmic domain to 18 residues (Fig. 1A). Construct
pCM14.PN10 is similar to pCM14.Pst10 but in the context
of the 48-residue ROD14 Env cytoplasmic tail. We previ-
ously showed that ROD10.env1, an Env-deficient mutant of
HIV-2 ROD10, had low particle release efficiency but could
be rescued by providing in trans an envelope protein active
for particle release (Bour et al., 1996). The chimeric enve-
lope proteins were expressed in HeLa cells and assessed in
pulse-chase experiments for their ability to restore in trans
efficient particle release by ROD10.env1. Expression of the
CMV-driven envelope genes was Rev-dependent in this
context and therefore required the presence of ROD10.env1
in the same cell. As shown in Fig. 1B, the ROD14 as well
as the chimeric envelopes were properly expressed and
present in similar amounts in all samples. The presence of
different Env variants had no apparent effect on the synthe-
sis or maturation of Gag proteins detected on the gels.
However, the presence of the CMV-driven plasmids ex-
pressing the ROD14.Pst10 and ROD14.PN10 envelopes
generated a redistribution of Gag proteins from the cell to
the virion fraction, indicating that these envelope species
were able to rescue the particle release defect of
ROD10.env1 (Fig. 1B). No such effect was observed in the
presence of the ROD14 envelope (Fig. 1B). To quantify the
ability of the different envelope species to promote viral
particle release, the radioactive intensity of the bands cor-
responding to the p58gag, p26/27 CA, and p16 MA was
measured and the ratio of virion-associated Gag proteins to
the total combined cellular and viral Gag proteins was
calculated and plotted as a function of time (Fig. 1C). As
previously reported, particle release efficiency by the
ROD14 molecular clone was low and similar to that ob-
served for an Env-deficient mutant of ROD10 (Bour et al.,
1999b). Transfer of a PstI fragment from the active ROD10
envelope protein restored particle release activity to the
ROD14 envelope (Fig. 1C, ROD14.Pst10). Furthermore,
particle release efficiency of the ROD14.PN10 chimeric
Env was very similar to that of ROD14.Pst10. Since the two
chimeras differ only by the length of their cytoplasmic tail,
these data further confirm our previous finding that the
length of the HIV-2 ROD Env cytoplasmic domain does not
Fig. 1. Delineation of the HIV-2 ROD Env residues involved in regulating viral particle release. (A) Schematic representation of the CMV promoter-driven
ROD10/ROD14 Env chimeric constructs. DNA fragments obtained by restriction digest of the ROD10 Env-expression vector pCM10 with PstI were
introduced into the ROD14 Env pCM14 vector to give rise to pCM14.Pst10. The pCM14.PN10 chimera was obtained by replacing the NcoI fragment in
pCM14.Pst10 with that of pCM14. The amino acid sequences surrounding positions 422 and 598 are indicated on the bottom. (B) HeLa cells were transfected
with 20 g of the Env-deficient pROD10.env1 molecular clone in the presence of 10 g of either pCM14 (ROD14), pCM14.Pst10 (ROD14.Pst10), or
pCM14.PN10 (ROD14.PN10). The ability of the chimeric envelopes to enhance particle release by ROD10.env1 was assessed by pulse-chase analysis. Cells
were pulse-labeled for 30 min with Trans35S-Label (1 mCi/ml) and chased for the indicated times. At each time point, aliquots of the cells and the
virus-containing supernatants were harvested, and virus particles present in the culture medium were pelleted. Viral proteins were recovered by immuno-
precipitation of both the cell lysate and the pelleted virus fractions with a pool of anti-HIV-2 patient sera, separated on 12% SDS–PAGE, and visualized by
fluorography. The HIV-2 major Gag proteins p58gag, p26–27CA, and p16MA as well as the HIV-2 envelope glycoprotein precursor gp140 are identified on
the left. (C) Bands corresponding to the HIV-2 major Gag proteins in (B) were quantified with an image analyzer. The efficiency of particle release at each
time point was calculated by dividing the amount of Gag proteins present in the pelleted virus fraction by the total of cell- and virus-associated Gag proteins.
The ratio of virion-associated versus total Gag protein was then plotted as a function of time.
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influence viral particle release (Bour et al., 1999b). These
results indicate that the particle release activity of ROD Env
is indeed regulated and that the sequences important for this
regulation are comprised within the PN10 fragment.
A naturally occurring substitution at position 598
regulates the envelope activity on viral particle
release in HeLa cells
The ROD10 and ROD14 envelope sequences encoded by
the PN10 fragment differ by only two amino acids: a lysine-
to-arginine substitution at position 422 and an alanine-to-
threonine substitution at position 598 (Fig. 1A). To directly
address the role of these residues in the regulation of the
envelope’s particle release activity, the residues at positions
422 and 598 in ROD14 were changed, either singly or in
combination, to those present in ROD10. The mutations
were introduced into the pROD1014 molecular clone,
which carries the ROD14 env gene in the backbone of
ROD10, and their effect on particle release was assessed by
pulse-chase analysis and immunoprecipitation as described
above (gels not shown). Quantification of the particle re-
lease efficiency of the ROD1014.422RK, ROD1014.598TA,
and ROD1014.RK/TA double mutant showed that the 422RK
mutation had little effect on the activity of the ROD14
envelope (Fig. 2, compare ROD1014 and ROD1014.422RK).
In contrast, the 598TA mutation alone led to a nearly three-
fold increase in particle release (Fig. 2, ROD1014.598TA).
Such virus release efficiency is very similar to that observed
for the wild-type ROD10 isolate (Bour et al., 1999b). These
data indicate that the residue at position 598 is critical for
regulating the envelope’s Vpu-like activity. The presence of
the 422RK mutation in addition to 598TA did not signifi-
cantly improve the particle release activity from HeLa cells,
in agreement with data obtained with the 422RK single
mutant (Fig. 2, ROD1014.RK/TA). The 598TA mutation is
therefore necessary and sufficient to restore particle release
activity in the inactive ROD14 envelope in transfected
HeLa cells.
Cell-type-dependent requirement for the 422RK/598TA
double mutation for efficient particle release
Both the HIV-1 and the HIV-2 envelope proteins have
the ability to form intracellular complexes with the CD4
receptor that can result in the blockage of both CD4 and Env
in the endoplasmic reticulum (Bour et al., 1991, 1995).
Since we have previously shown that the ROD10 Env is
Fig. 1 (continued)
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unable to enhance particle release when trapped in the ER
(Bour et al., 1996), we addressed whether the ability of the
598TA mutation to restore particle release activity to the
ROD14 envelope in HeLa cells could also be observed
during the course of a productive infection in CD4 cells.
To guarantee equal initial infectivity of all preparations
regardless of Env mutations, viruses were pseudotyped with
the vesicular stomatitis virus G protein (VSV-G). To verify
that the VSV-G envelope-pseudotyped viruses behaved
similarly to their wild-type counterparts with regard to par-
ticle release, HeLa cells were infected with ROD1014/VSV
and ROD1014.598TA/VSV and a pulse-chase experiment
was performed. As shown in the top of Fig. 3A, the presence
of the 598TA mutation enhanced the rate of export of
virus-associated p24. Quantitation of the viral Gag proteins
revealed a remarkable fourfold enhancement of viral parti-
cle release by the ROD1014.598TA mutant as compared to
the original ROD1014 (Fig. 3A, bottom). This result is
consistent with data presented in Fig. 2 and shows that
VSV-G pseudotyping of the ROD1014 virus does not alter
its particle release efficiency.
VSV-G-pseudotyped virus preparations were subse-
quently used to infect CD4 12D7 and H9 cells. Cells were
infected with equal amounts of ROD1014, ROD1014.422RK,
ROD1014.598TA, and ROD1014.RK/TA virus stocks for
4 h at 37°C. The cells were then washed to remove residual
input virus and virus replication was monitored by deter-
mining the reverse transcriptase (RT) activity in the culture
supernatants harvested at 2-day intervals (Fig. 3B). In 12D7
cells, peak RT production occurred at 8 days postinfection
for all viruses tested; however, the 598TA and RK/TA
mutants produced over twofold higher RT activity at peak
virus infection than ROD1014 and the 422RK mutant. This
result is typical of the situation observed for the HIV-1 Vpu
protein (Strebel et al., 1988; Yao et al., 1992) and indicates
that the 598TA mutation led to an activation of the Vpu-like
particle release enhancement activity of the HIV-2 ROD
Env. This closely parallels the situation observed in HeLa
cells and shows that, even in the presence of CD4 in 12D7
cells, the residue at position 598 in the ROD envelope
protein is sufficient to enhance viral particle release. Inter-
estingly, in H9 cells, mutation of residue 598 alone
(pROD1014.598TA) was not sufficient to restore efficient
virus replication. Instead, both the 598TA and the 422RK
mutations were required to achieve high levels of viral
particle production (Fig. 3B, pROD1014.RK/TA). These
results demonstrate a functional codependence between res-
idues 422 and 598 in the HIV-2 ROD envelope protein for
regulation of virus release from certain cell types and might
explain why these two mutations have coevolved.
Fig. 2. The effect of the 422RK and 598TA mutations on ROD14 particle release was assessed by pulse chase after transfection of HeLa cells with 30 g
of the indicated molecular clone DNAs. Pulse-chase analysis, immunoprecipitation, and gel electrophoresis were performed as described in Fig. 1 (not
shown). Gag proteins detected on the gels were quantified with an image analyzer. The efficiency of particle release at each time point was calculated as
described in the legends to Fig. 1 and the ratio of virion-associated versus total Gag proteins was plotted as a function of time.
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Proteolytic cleavage is required to activate the ROD10
Env particle release activity
To better define the molecular mechanism by which
residues 422 and 598 regulate the particle release activity of
the HIV-2 ROD Env, we performed a comparative bio-
chemical characterization of the wild-type ROD10 and the
three ROD14 envelope mutants described above. All anal-
yses were performed with full-length cytoplasmic tail en-
velope proteins. No significant differences were observed at
the level of protein synthesis, stability, cell-surface expres-
sion, or virion incorporation (data not shown). This sug-
gested that the inability of the ROD14 Env to enhance
particle release was not the result of a gross modification of
the envelope’s structure. Since the mature TM subunit of
HIV-2 Env has structural and topological features similar to
that of the HIV-1 Vpu protein, we examined whether the
Vpu-like activity of the ROD10 Env required proteolytic
cleavage of the gp140 precursor and release of the mature
gp36 TM subunit. If so, then subtle differences in the
relative precursor processing efficiencies could account for
the observed effects. To address this question, HeLa cells
were transfected with either wild-type pROD10 plasmid
DNA or an Env cleavage-deficient variant (pROD10.Clv)
obtained by substituting a threonine for an arginine at po-
sition 511 to inactivate the envelope cleavage site, as pre-
viously described (Freed and Myers, 1992). A similar cleav-
age mutant in the context of the full-length cytoplasmic tail
Env (pROD10FL.Clv) was also expressed in HeLa cells.
Pulse-chase labeling and immunoprecipitations were per-
formed as described above and viral Gag proteins were
visualized and quantified as shown in Fig. 4A. The envelope
cleavage site mutation had no apparent effect on the effi-
ciency and kinetics of Gag processing, as demonstrated by
the appearance of the p26/27 mature capsid products in all
samples (Fig. 4A, insets). Quantification of the particle
release efficiency demonstrated efficient particle release for
wild-type ROD10 with 40% of the total Gag proteins found
in the form of secreted viral particles within 60 min of chase
(Fig. 4A, ROD10). In contrast, particle release efficiencies
for both the truncated and the full-length versions of the
cleavage-deficient envelope protein were significantly re-
duced and similar to that observed for the inactive ROD14
Env (Fig. 4A, ROD10.Clv, ROD10-FL.Clv). These results
demonstrate that proteolytic cleavage of the Env precursor
is required to activate its particle release activity.
We next examined whether the lack of activity of the
ROD14 envelope protein could be due to inefficient precur-
sor cleavage. To ensure quantitative detection of the mature
gp36 product, a FLAG epitope tag was added to the C-
terminus of full-length ROD10 and ROD14 envelope pro-
teins in the context of the pROD-A1 subgenomic construct.
Plasmids pROD-A2.flg, pROD-A14FL.flg, as well as the
cleavage mutant pROD-A2Clv.flg construct were trans-
fected into HeLa cells. Thirty-six hours posttransfection,
cells were lysed in detergent buffer and equal amounts of
protein extracts were subjected to SDS–PAGE. Proteins
were transferred to PVDF membranes and probed in West-
ern blot with anti-FLAG M2 antibodies. As shown in Fig.
4B, all three Env species were expressed at similar rates, as
judged by the intensity of the gp140 precursor band. As
expected, no mature gp36 product was observed in the case
of the 511RT cleavage mutant (Fig. 4B, ROD10FL.Clv). In
contrast, efficient cleavage of both the ROD10 and the
ROD14 envelope proteins was observed, yielding the ma-
ture gp36 TM subunit (Fig. 4B, ROD10FL and ROD14FL).
The calculated gp36/gp140 ratios, represented graphically
in Fig. 4B, further demonstrate that the active ROD10 and
inactive ROD14 envelope proteins have indistinguishable
cleavage efficiencies. These data suggest that although pre-
cursor cleavage is required for activation of the ROD Env
viral release activity, it does not account for the lack of
activity of the ROD14 envelope glycoprotein.
The ROD14 envelope has a trans-dominant negative
effect on viral particle release
Another possibility to account for the lack of activity of
the ROD14 Env may involve subtle changes in the enve-
lope’s tertiary structure. Indeed, it has been shown that the
equivalent HIV-1 protein, Vpu, requires the proper forma-
tion of higher order homooligomeric structures to exert its
positive effect on viral particle release (Schubert et al.,
1996b). In addition, we found that expression of CD4 at the
cell surface efficiently blocked the virus-release activity of
Vpu, presumably through the formation of inactive heteroo-
ligomeric complexes between CD4 and Vpu (Bour et al.,
1999a). Accordingly, the ability or inability of HIV-2 en-
velope molecules to facilitate virus release may depend on
their ability to form proper oligomers structures. We ad-
dressed this possibility by testing whether coexpression of
the inactive ROD14 envelope with the active ROD10 en-
velope could interfere with the activity displayed by the
ROD10 envelope protein. For that purpose, HeLa cells were
cotransfected with the Env-defective pROD10.env1 or
wild-type pROD10 plasmid DNA and CMV-driven vectors
expressing either the ROD10 (pCM10) or the ROD14
(pCM14) Env proteins. An envelope-deficient mutant of
pCM10 (pCM10.env1) was used as a control. Cells were
pulse-labeled for 30 min with [35S]methionine and the par-
ticle release efficiency was assessed by pulse-chase analy-
sis. Labeled Env products from the cell fractions were
immunoprecipitated and separated on SDS–PAGE. As
shown in Fig. 5A, the ROD10 and ROD14 envelope pro-
teins were efficiently expressed in trans from their respec-
tive CMV-driven vectors; no major differences in their
relative expression levels were observed. The presence of
the ROD10 or ROD14 Env in trans did not lead to detect-
able changes in the synthesis or rate of maturation of Gag
protein, whether in the context of ROD10.env1 or wild-type
ROD10 (data not shown). Gag proteins immunoprecipitated
at each time point of the chase from both the cell and the
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Fig. 3. Cell-type dependence of HIV-2 ROD particle release efficiency. (A) VSV-G-pseudotyped preparations of ROD1014 and ROD1014.598TA were used
to infect HeLa cells. Twenty-four hours postinfection, cells were pulse-labeled for 30 min with Trans35S-Label and chased for the indicated times. Panel 1:
immunoprecipitation and detection of viral proteins is as described for Fig. 1. Panel 2: bands corresponding to the major HIV-2 Gag proteins in panel 1 were
quantified with an image analyzer and the efficiency of particle release at each time point was calculated as described for Fig. 1. (B) Pseudotyped HIV-2 virion
preparations were used to infect 12D7 and H9 cells. Cells were infected for 5 h at 37°C with equal reverse-transcriptase units of the viral species indicated.
The kinetics of de novo virus production was assessed by monitoring the reverse transcriptase activity released in the culture medium over time.
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supernatant fractions were quantified as described above
and particle release efficiency was plotted graphically in
Fig. 5B. As described previously, the Env-defective
ROD10.env1 had a low particle release efficiency (Bour et
al., 1996). Coexpression of the ROD10 Env led to a twofold
enhancement of particle production, in agreement with pre-
vious studies (Bour et al., 1996). Interestingly, expression of
the ROD14 envelope protein in trans did not inhibit the
particle release efficiency of the Env-defective
ROD10.env1. Indeed, the particle release efficiency of
ROD10.env1 was identical whether expressed in the com-
plete absence of Env proteins (Fig. 5B, ROD10.env1 
pCM10.env1) or in the presence of the ROD14 Env
(ROD10.env1  pCM14). These data indicate that the low
particle release efficiency of the ROD14 virus is due to a
lack of activity on viral production rather than a possible
inhibitory activity of the ROD14 Env. In agreement with
our previous data (Bour et al., 1996), the particle release
efficiency of ROD10 in the presence of the empty CMV-
expression vector was high (Fig. 5B, ROD10 
pCM10.env1) and was unaffected by the coexpression of
the ROD10 envelope in trans (Fig. 5B, ROD10  pCM10).
In contrast, coexpression of the ROD14 envelope protein
had a pronounced inhibitory effect resulting in a twofold
drop in the ROD10 particle release efficiency (Fig. 5B,
ROD10  pCM14). In fact, the efficiency of ROD10 virus
release in the presence of the ROD14 envelope was very
similar to that observed for the envelope-deficient
ROD10.env1 mutant (see Fig. 1B), suggesting a complete
inhibition of the ROD10 Env virus-release activity by the
ROD14 Env protein. This trans-dominant negative activity
of the ROD14 envelope on ROD10 but not ROD10.env1
strongly suggests that the virus release activity of ROD10
Env depends on the formation of proper homooligomeric
structures. By intercalating itself into functional ROD10
Env oligomers, the ROD14 Env might be able to perturb the
structure of the ROD10 multimer and inactivate its particle
release function. The ability of a given Env protein to form
such structures is therefore likely the determining factor in
activating its viral particle release activity.
Discussion
Regulation of virus release is a classical example of how
different solutions to common problems can evolve even in
closely related viruses. While HIV-1 uses a unique acces-
sory protein, Vpu, to facilitate virus release, a similar ac-
tivity is controlled by the envelope glycoprotein of some
HIV-2 isolates, including ROD10 and HIV-2 ST, as well as
some SIV isolates (Bour et al., 1996; Bour and Strebel,
1996; Ritter et al., 1996). Interestingly, even though both
the HIV-2 ROD10 and the ST isolate encode envelope
proteins with Vpu-like activities, the structural domains
within Env responsible for these activities appear to differ.
In the case of the ST isolate, this biological activity is
regulated by the length of the envelope’s cytoplasmic tail.
Indeed, the ST2 variant, which envelope is truncated to 17
cytoplasmic residues, has lost the ability to enhance virus
release (Ritter et al., 1996). In contrast, the particle release
activity of the ROD10 envelope is not regulated by the
length of its cytoplasmic tail (Bour et al., 1999b) but, as
shown in this study, requires sequences in the ectodomain of
the TM subunit. Despite these differences in the structural
Fig. 3 (continued)
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requirements, it is plausible that regulation of virus release
in HIV-1, HIV-2, and SIV is based on the same molecular
mechanism involving homooligomerization of the effector
protein.
Our biochemical characterization suggests that the par-
ticle release activity of the HIV-2 ROD envelope protein
can be regulated by a single amino acid change at position
598 in the gp36 ectodomain. This conclusion is based on the
characterization of the envelope protein of ROD14, an
HIV-2 infectious molecular clone closely related to ROD10
Fig. 4. Effect of ROD Env cleavage efficiency on particle release activity. (A) HeLa cells were transfected with plasmid DNA encoding the indicated HIV-2
species and subjected to pulse-chase analysis as described above. Viral capsid proteins recovered in the cell and virus fractions at each time point are shown
on the right. Bands corresponding to the major HIV-2 Gag proteins (p58gag, p26–27CA, and p16MA) were quantified and the particle release efficiency was
calculated and plotted as a function of time. (B) HeLa cells were transfected with plasmids pROD-A2.flg (ROD10FL), pROD-A14FL.flg (ROD14FL), and
pROD-A2clv.flg (ROD10FL-Clv). Cells were lysed in detergent buffer and equal amounts of the lysates were separated by SDS–PAGE. The FLAG
epitope-tagged gp140 Env precursor and gp36 mature TM subunit were detected by Western blotting using the M2 anti-FLAG antibody. Proteins were
quantified and the cleavage efficiency was calculated and plotted as the ratio of gp36/gp140 for each envelope protein species.
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(Ryan-Graham and Peden, 1995). Pulse-chase experiments
performed in HeLa cells revealed that the envelope protein
of ROD14 was unable to promote viral release but could be
made functional by changing the threonine at position 598
to the alanine present in ROD10 Env. This mutation re-
stored full particle release activity in the ROD14 Env with-
out generating a broad modification of the envelope’s bio-
chemical properties such as synthesis, stability, transport,
cleavage, surface expression, and virion incorporation. In
HeLa cells, the 598TA mutation was necessary and suffi-
cient to modulate particle release activity. However, studies
in the CD4-positive H9 and 12D7 T cell lines also revealed
a role for the residue at position 422. Indeed, only in the
presence of the 422RK mutation did the 598TA substitution
lead to enhanced particle production in H9 cells. The resi-
due at position 422 is located in the C4 domain of the SU
subunit, a domain known to mediate CD4 binding, fusion
activity, and viral tropism (Keller et al., 1993; Otteken et al.,
1993), while the residue at position 598 is located within a
highly conserved region of the HIV-2 TM subunit (Korber
et al., 1997) and is an alanine in most HIV-2 and SIV
isolates, including ROD10. Only one naturally occurring
isolate other than ROD14 has a threonine at position 598:
HIV-2 UC2 (Barnett et al., 1996). Interestingly, this isolate
also bears the ROD14 arginine at position 422 in the C4
domain of the SU subunit (Barnett et al., 1996). It is there-
fore tempting to speculate that the coselection of specific
residues at positions 422 and 598 is biologically significant
and correlates with efficient virus replication in some cell
types. Nevertheless, residue 422 is not as conserved as
residue 598 (Kuiken et al., 2000) and it is possible that the
phenotype associated with the change at position 422 (i.e.,
increased envelope fusion activity) is not as critical for virus
replication or might be accomplished through mutations in
Fig. 5. Negative trans-dominant activity of the ROD14 Env on HIV-2 ROD10 particle release. (A) HeLa cells were transfected with 20 g of the
pROD10.env1 or pROD10 plasmid in the presence of 10 g of either the Env-deficient plasmid pCM10.env1, the ROD10 Env-expressing vector pCM10,
or the ROD14 Env-expressing plasmid pCM14. Expression of the various HIV-2 Env proteins is shown after immunoprecipitation of the cell fraction at each
time point. (B) Viral particle release of cells transfected in (A) was assessed by pulse-chase analysis and immunoprecipitation. HIV-2 Gag proteins were
quantified with an image analyzer. The efficiency of particle release at each time point was calculated as described in the legend to Fig. 1 and the ratio of
virion-associated versus total Gag proteins was plotted as a function of time.
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other regions of the envelope protein. We did not observe
the emergence of revertants in prolonged cultures of H9
cells infected with the particle-release defective ROD1014
and ROD1014.422RK. In addition, sequencing of viral ge-
nomes obtained from these cultures over time did not show
substitutions at positions 422 or 598. In fact, the entire env
sequence was remarkably stable over time. These data are
not surprising in light of the fact that, similar to the situation
observed for the HIV-1 Vpu protein, the presence of an
envelope protein active in promoting particle release is not
essential for HIV-2 ROD replication in tissue culture sys-
tems (Strebel et al., 1988). As with Vpu, the full effect of
particle release-promoting activities might only be seen in
vivo where more complex selection pressures are exerted on
the virus. In this regard, a number of animal studies have
recently demonstrated a role for Vpu in disease progression
and maintenance of high viral loads as well as reversion of
Vpu-defective viruses (McCormick-Davis et al., 1998; Ste-
phens et al., 2002).
Our attempts to decipher the molecular mechanism gov-
erning the HIV-2 Env-facilitated viral particle release did
not reveal any tangible differences in the biochemical prop-
erties of the inactive (ROD14) and the active
(ROD14.598TA) envelope species. These results are con-
sistent with a model in which this biological activity of the
HIV-2 envelope can be switched on or off without affecting
its other essential functions. Mechanistically, we have dem-
onstrated a need for proper cleavage of the gp140 Env
precursor into mature SU and TM to activate the particle
release function. Since we previously demonstrated a lack
of activity of the SU subunit alone (Bour and Strebel, 1996),
these data indicate that the mature TM subunit, containing
residue 598, harbors the functional domain for enhanced
viral release. These findings also suggest a possible expla-
nation for the interdependence of residues 422 and 598.
Indeed, it is conceivable that residue 422, located in the SU,
is involved in interactions with domains of the mature TM
subunit (and possibly residue 598 directly) following cleav-
age of the gp140 precursor. Changes in residues 422 and
598 could therefore affect the rate of shedding of the SU
subunit and may be critical for the activation of the particle
release activity catalyzed by the TM subunit.
An important clue concerning the possible mechanism of
action of the HIV-2 Env is our finding that the inactive
ROD14 had a trans-dominant negative effect on the active
ROD10 envelope. This trans-dominant activity is indicative
of direct protein–protein interactions between the two en-
velope species, most likely in the form of heterooligomers.
The tertiary structure of the envelope may thus be critical to
activate a particle release-promoting activity. Such tertiary
structure, presumably formed by trimers or tetramers of the
envelope, could be functionally equivalent to the oligomeric
structures formed by the HIV-1 Vpu protein (Maldarelli et
al., 1993). In the case of Vpu, oligomerization is critical for
the formation of ion channels believed to mediate its parti-
cle release activity (Ewart et al., 1996; Grice et al., 1997;
Schubert et al., 1996b). Although we do not have direct
evidence that the ROD10 envelope forms ion channels,
oligomers of the HIV-1 envelope have been shown to form
membrane pores (Arroyo et al., 1995). This finding could
extend to HIV-2 since both envelopes oligomerize through
common domains (Center et al., 1997; Doms et al., 1990).
Alternatively, the 598TA mutation might change the effi-
ciency and/or location of the disulfide bond being formed
between residues 597 and 603 (Fig. 1A). This in turn could
modify the conformation of the TM subunit in a way that
influences its biological activity. Further characterization of the
HIV-2 ROD Env particle release activity is therefore needed to
not only better understand the mechanism of Env-mediated
regulation of virus release but, in addition, to gain insights
into the process of retroviral particle formation and release.
Materials and methods
Recombinant plasmid DNA
Construction of the pROD10 and pROD14 molecular
clones of HIV-2 has been described elsewhere (Bour et al.,
1996; Ryan-Graham and Peden, 1995).
The pROD-A1 plasmid and its envelope-deficient variant
pROD-A1.env1 are derivatives of pROD10 that lack the
gag and pol genes but express all other viral genes (Bour et
al., 1996).
pCM10 expresses the ROD10 envelope protein under the
transcriptional control of the cytomegalovirus (CMV) early
promoter. This vector is similar to the previously described
pCM5-Env (Bour and Strebel, 1996) from which it differs
by the absence of an NcoI site in the CMV promoter.
Plasmid pCM14 is similar to pCM10 but encodes the
ROD14 envelope. The construct was generated by cloning
the PCR-amplified full-length ROD14 envelope sequence
flanked by XbaI and BamHI restriction sites into the corre-
sponding sites in pCM10.
pROD1014 is a derivative of the ROD10 molecular
clone bearing the envelope gene from ROD14. This plasmid
was constructed by cloning a 2397-bp PCR-amplified
BsaAI-BsmI fragment from pROD14 into the corresponding
sites in pROD10. The same insert was cloned into
pROD-A1 to give rise to pROD-A14.
Site-directed mutagenesis
Site-directed mutagenesis of the ROD10 and ROD14
envelopes was performed using the Altered Sites Mutagen-
esis System (Promega, Madison, WI). Plasmids pALT-1
and pALT-11 served as templates for mutagenesis of the
envelope cytoplasmic tail. The plasmids were constructed
by cloning a 793-bp NcoI fragment (Env residues 608–858)
from pROD10 and pROD14, respectively, into pAL-
TER.Ex1 (Promega). The mutations were introduced into
the pROD10 or pROD1014 molecular clones as an NcoI
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fragment. pROD10.FL (720ZQ, a full-length 157-residues
ROD10 envelope) was constructed by substituting a CAG
for a TAG codon at position 2158. Plasmid pALT-17 served
as template for the introduction of the 422RK, 598TA, and
422RK/598TA mutations. The vector was constructed by
cloning a 1143-bp PstI fragment from pROD14 (Env resi-
dues 391–772) into pALTER.Ex1. Mutant envelopes were
transferred as a PstI fragment into pCM14 and subsequently
from the pCM14 mutants into pROD1014 as a PmaCI-BsmI
fragment and into pROD-A14 as a PmlI-BsmI fragment.
Plasmid pALT-14 results from the mutagenesis of
pALT-1 that removed the premature stop codon in the
cytoplasmic tail of the ROD10 envelope. pALT-14 was
used in turn as mutagenesis template to generate a C-
terminal FLAG epitope-tagged (Eastman Kodak, Rochester
NY, USA) version of the full-length ROD envelope pro-
teins. An 817-bp NcoI containing the fused FLAG epitope
was subsequently transferred from pALT-14 into pROD-A1
and pROD-A14 to generate pROD-A2.flg and pROD-
A14FL.flg, respectively.
Plasmid pALT-24 was constructed by cloning a 1143-bp
PstI fragment from pROD10 (Env residues 391–772) into
pALTER.Ex1. Plasmid pALT-25 results from the mutagen-
esis of pALT-24 to introduce a 511RT mutation that inac-
tivates the ROD10 envelope cleavage site as previously
described (Freed and Myers, 1992). The 511RT mutation
was transferred from pALT-25 into pROD10 as described
above to give rise to pROD10.Clv. A full-length envelope
version of the cleavage mutant (pROD10FL.Clv) was ob-
tained by transferring a 793-bp NcoI fragment from
pROD10.FL into pROD10.Clv. The 511RT mutation was
carried into pROD-A2.flg as a 2787-bp BamHI-HindIII
fragment to give rise to pROD-A2Clv.flg.
Cells, infection, and transfection
HeLa cells (ATCC CCL2) were propagated in Dulbec-
co’s modified Eagle’s medium (DMEM) containing 10%
fetal bovine serum (FBS). H9 and 12D7 cells were propa-
gated in RPMI 1640 containing 10% FBS.
For transfection, HeLa cells were grown to near conflu-
ence in 25 cm2 flasks (5  106 cells per flask). The medium
was replaced prior to transfection and calcium phosphate
precipitated plasmid DNA (25–30 g) was added to the
cells. After 4 h incubation at 37°C, the cells were subjected
to a glycerol shock for 2.5 min. The cultures were then
washed once with PBS and maintained in 5 ml DMEM/FBS
for 16 h.
Infections were initiated in H9 or 12D7 cells by infection
with VSV-G-pseudotyped viral particles. VSV-G-
pseudotyped virus preparations were obtained as follows:
semiconfluent 293T cells in T75 flasks were contransfected
with 20 g proviral pROD1014 plasmid DNA or its mutants
and 2 g pCMV-G expressing the VSV-G protein using the
Lipofectamine Plus reagents (Life Technology). Forty-eight
hours later, the culture supernatants were harvested, clari-
fied by centrifugation, and filtrated through 0.45-mm
Sterivex-HX filter (Millipore), followed by ultracentrifuga-
tion at 25,000 rpm for 1 h in an SW41 rotor. The virus
pellets were resuspended in 1 ml RPMI-1640 supplemented
with 10% FCS. Cells were infected at 3  106 cells/ml with
300,000 cpm RT activity of concentrated VSV-G
pseudotyped virus for 4 h at 37°C. Fresh medium was added
to 5 ml final and the infection kinetics were monitored by
reverse transcriptase assay. The cultures were also moni-
tored for cytopathic effects and formation of syncytia by
examination under the light microscope.
Antisera and antibodies
Serum from an asymptomatic HIV-1 seropositive patient
(TP serum) supplemented with a pool of HIV-2 patient sera
and a rabbit antiserum to HIV-2ST gp120 (contributed to the
AIDS Research and Reference Reagent Program by Drs.
Saladin Osmanov and Raymond Sweet, respectively) were
used to detect HIV-2 Gag and envelope proteins.
A peroxidase-conjugated monoclonal anti-FLAG anti-
body (M2, Sigma Chemical, St. Louis, MO) was used for
Western blot detection of the C-terminal flagged ROD10
and ROD14 envelope proteins.
Pulse-chase and immunoprecipitation
Viral particle release was assessed by pulse-chase anal-
ysis and immunoprecipitation of viral proteins was secreted
into the culture supernatant in the form of pelletable virions
as recently described (Bour et al., 1996; Bour and Strebel,
1996). Briefly, transfected HeLa cells were pulse-labeled
with 1 mCi/ml Trans35S-Label (ICN Biomedical, Inc.,
Costa Mesa, CA, USA) for 30 min. Cells were subjected to
a chase at 37°C in 300 l of prewarmed DMEM/FBS for the
indicated chase periods. At each time point, cells were
collected and lysed in 400 l of NP-40-DOC buffer [20 mM
Tris–HCl pH 8, 120 mM NaCl, 2 mM EDTA, 0.5% DOC,
1% NP-40]. The culture supernatants were filtered through
0.45-m cellulose acetate Spin-X centrifuge tube filters
(Corning Costar Corp., Cambridge, MA) to remove residual
cells and cell debris. Virus particles were then pelleted from
cell-free supernatants in a refrigerated Eppendorf microcen-
trifuge (4°C, 90 min, 16,000 g). Pelleted virions were lysed
in 400 l NP-40-DOC buffer. Cell lysates were precleared
with Protein A–Sepharose beads (Sigma Chemical) and
immunoprecipitated with a 1:1 mixture of TP serum and
HIV-2 patient serum pool. Immunoprecipitates were solu-
bilized by boiling in sample buffer containing 2% sodium
dodecyl sulfate (SDS), 1% -mercaptoethanol, 1% glycerol,
65 mM Tris–hydrochloride (pH 6.8), and separated by
SDS–PAGE using 12% gels. Gels were fixed, incubated for
20 min in Enlightning (NEN Research Products, Boston,
MA), and dried. Radioactive bands were visualized by flu-
orography using Bio-Max MR films (Eastman Kodak).
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Quantitation of the relevant bands was performed using a
Fujix BAS 2000 Bio-Image Analyzer.
Western blotting
Cell lysates were prepared from transfected HeLa cells
24-h posttransfection by lysis in NP-40-DOC buffer, as
described above. A Bio-Rad protein assay was performed
according to manufacturer’s protocol to normalize the
amount of protein for separation. Five to ten micrograms of
proteins per lane were separated on 10% polyacrylamide–
SDS gels. Proteins were then transferred onto PVDF mem-
branes and probed with a 1/2000 dilution of anti-flag M2
peroxidase-conjugated antibody (Sigma Chemical). Pro-
teins were visualized by ECL (Amersham Biotech, Piscat-
away, NJ).
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